The Intestinal Microbiome and the Metabolic Syndrome-How Its Manipulation May Affect Metabolic-Associated Fatty Liver Disease (MAFLD)
- PMID: 37754239
- PMCID: PMC10527723
- DOI: 10.3390/cimb45090455
The Intestinal Microbiome and the Metabolic Syndrome-How Its Manipulation May Affect Metabolic-Associated Fatty Liver Disease (MAFLD)
Abstract
Metabolic-associated fatty liver disease (MAFLD) is now the predominant liver disease worldwide consequent to the epidemic of obesity. The intestinal microbiome (IM), consisting of the bacteria, fungi, archaea, and viruses residing in the gastrointestinal tract, plays an important role in human metabolism and preserving the epithelial barrier function. Disturbances in the IM have been shown to influence the development and progression of MAFLD and play a role in the development of metabolic syndrome (MS). The main treatment for MAFLD involves lifestyle changes, which also influence the IM. Manipulation of the IM by fecal microbial transplantation (FMT) has been approved for the treatment of recurrent Closteroides difficile infection. This may be administered by endoscopic administration from the lower or upper GI tract. Other methods of administration include nasogastric tube, enema, and oral capsules of stool from healthy donors. In this narrative review, we elaborate on the role of the IM in developing MS and MAFLD and on the current experience with IM modulation by FMT on MAFLD.
Keywords: fatty liver; fecal microbial transplantation; intestinal microbiome.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Treating the Metabolic Syndrome by Fecal Transplantation-Current Status.Biology (Basel). 2021 May 20;10(5):447. doi: 10.3390/biology10050447. Biology (Basel). 2021. PMID: 34065241 Free PMC article. Review.
-
Manipulation of the intestinal microbiome-a slow journey to primetime.World J Clin Cases. 2023 Jul 26;11(21):4975-4988. doi: 10.12998/wjcc.v11.i21.4975. World J Clin Cases. 2023. PMID: 37583860 Free PMC article. Review.
-
Mapping the human oral and gut fungal microbiota in patients with metabolic dysfunction-associated fatty liver disease.Front Cell Infect Microbiol. 2023 Apr 26;13:1157368. doi: 10.3389/fcimb.2023.1157368. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37180439 Free PMC article.
-
Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease.Nutrients. 2021 Mar 21;13(3):1013. doi: 10.3390/nu13031013. Nutrients. 2021. PMID: 33801023 Free PMC article.
-
Gut microbiome and metabolic-associated fatty liver disease: Current status and potential applications.World J Hepatol. 2023 Jul 27;15(7):867-882. doi: 10.4254/wjh.v15.i7.867. World J Hepatol. 2023. PMID: 37547030 Free PMC article. Review.
Cited by
-
The Many Faces of Metabolic Dysfunction-Associated Fatty Liver Disease Treatment: From the Mediterranean Diet to Fecal Microbiota Transplantation.Medicina (Kaunas). 2024 Mar 29;60(4):563. doi: 10.3390/medicina60040563. Medicina (Kaunas). 2024. PMID: 38674209 Free PMC article. Review.
-
The Visceral Adiposity Index and Its Usefulness in the Prediction of Cardiometabolic Disorders.Nutrients. 2025 Jul 20;17(14):2374. doi: 10.3390/nu17142374. Nutrients. 2025. PMID: 40732999 Free PMC article. Review.
-
The role of FGF21 in the interplay between obesity and non-alcoholic fatty liver disease: a narrative review.Rom J Morphol Embryol. 2024 Apr-Jun;65(2):159-172. doi: 10.47162/RJME.65.2.02. Rom J Morphol Embryol. 2024. PMID: 39020530 Free PMC article. Review.
References
-
- Lorenzo C., Williams K., Hunt K.J., Haffner S.M. The National Cholesterol Education Program—Adult Treatment Panel III, International Diabetes Federation, and World Health Organization Definitions of the Metabolic Syndrome as Predictors of Incident Cardiovascular Disease and Diabetes. Diabetes Care. 2007;30:8–13. doi: 10.2337/dc06-1414. - DOI - PubMed
-
- Khunti K., Taub N., Tringham J., Jarvis J., Farooqi A., Skinner T.C., Davies M.J. Screening for the Metabolic Syndrome Using Simple Anthropometric Measurements in South Asian and White Europeans: A Population-Based Screening Study. The Leicester Ethnic Atherosclerosis and Diabetes Risk (LEADER) Study. Prim. Care Diabetes. 2010;4:25–32. doi: 10.1016/j.pcd.2010.01.002. - DOI - PubMed
-
- Shiwaku K., Nogi A., Kitajima K., Anuurad E., Enkhmaa B., Yamasaki M., Kim J.-M., Kim I.-S., Lee S.-K., Oyunsuren T., et al. Prevalence of the Metabolic Syndrome Using the Modified ATP III Definitions for Workers in Japan, Korea and Mongolia. J. Occup. Health. 2005;47:126–135. doi: 10.1539/joh.47.126. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources